1. Republic of Korea In Vitro Diagnostics Market Outlook to 2018
- Clinical Chemistry Genetic Testing, Haematology, Histology
and Cytology, Immuno Chemistry, Infectious Immunology and
Microbiology Culture
Report Details:
Published:December 2012
No. of Pages: 263
Price: Single User License – US$2500
Republic of Korea In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic
Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and
Microbiology Culture
Summary
GlobalData’s new report, “Republic of Korea In Vitro Diagnostics Market Outlook to 2018 - Clinical
Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious
Immunology and Microbiology Culture” provides key market data on the Republic of Korea In Vitro
Diagnostics market. The report provides value (USD million), volume (units) and average price
(USD) data for each segment and sub-segment within market categories – Immuno Chemistry,
Infectious Immunology, Clinical Chemistry, Haematology, Microbiology Culture, Histology And
Cytology and Genetic Testing. The report also provides company shares and distribution shares
data for each of the aforementioned market categories. The report is supplemented with global
corporate-level profiles of the key market participants with information on company financials and
pipeline products, wherever available.
This report is built using data and information sourced from proprietary databases, primary and
secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
- Market size and company share data for In Vitro Diagnostics market categories – Immuno
Chemistry, Infectious Immunology, Clinical Chemistry, Haematology, Microbiology Culture,
Histology And Cytology and Genetic Testing.
- Annualized market revenues (USD million), volume (units) and average price (USD) data for

2. each of the segments and sub-segments within market categories. Data from 2004 to 2011,
forecast forward for 7 years to 2018.
- 2011 company shares and distribution shares data for each of the market categories.
- Global corporate-level profiles of key companies operating within the Republic of Korea In Vitro
Diagnostics market.
- Key players covered include F. Hoffmann-La Roche Ltd., Abbott Laboratories, Siemens
Healthcare, Beckman Coulter, Inc., Sysmex Corporation, Alere Inc. and others.
Reasons to buy
- Develop business strategies by identifying the key market categories and segments poised for
strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the Republic of Korea In Vitro
Diagnostics competitive landscape.
- Develop capital investment strategies by identifying the key market segments expected to
register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product
distribution – Identify, understand and capitalize.
Get your copy of this report @
http://www.reportsnreports.com/reports/213273-republic-of-korea-in-vitro-diagnostics-market-outlook-to-2018-
clinical-chemistry-genetic-testing-haematology-histology-and-cytology-immuno-chemistry-infectious-immunology-
and-microbiology-culture.html
Major points covered in Table of Contents of this report include
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 10
1.2 List of Figures 14
2 Introduction 17
2.1 What is This Report About? 17
3 In Vitro Diagnostics In Republic of Korea 18
3.1 In Vitro Diagnostics, Market Segmentation 18
3.2 In Vitro Diagnostics, Republic of Korea, Overall Revenue ($m), USD Constant, 2004-2018 19
3.3 In Vitro Diagnostics Market, Republic of Korea, Revenue Mix ($m), 2011 21
3.4 In Vitro Diagnostics Market, Republic of Korea, Category Contribution (%), 2011 22
3.5 In Vitro Diagnostics, Republic of Korea, Company Share (2010-2011) 29
4 Clinical Chemistry In Republic of Korea 31
4.1 Clinical Chemistry, Market Segmentation 31
4.2 Clinical Chemistry Market, Republic of Korea, Revenue Mix ($m), 2011 32
4.3 Clinical Chemistry Market, Republic of Korea, Segment Contribution (%), 2011 33
4.4 Clinical Chemistry Overall Revenue, (2004-2018) 34
4.4.1 Clinical Chemisty Analyzers, Revenue (2004-2018) 38

3. 4.4.2 Urine Analysis, Revenue (2004-2018) 42
4.5 Clinical Chemistry Distribution Share (2010-2011) 46
4.6 Clinical Chemistry, Republic of Korea, Company Share (2010-2011) 47
5 Genetic Testing In Republic of Korea 49
5.1 Genetic Testing, Market Segmentation 49
5.2 Genetic Testing Market, Republic of Korea, Revenue Mix ($m), 2011 50
5.3 Genetic Testing Market, Republic of Korea, Segment Contribution (%), 2011 51
5.4 Genetic Testing Overall Revenue, (2004-2018) 52
5.5 Genetic Testing Distribution Share (2010-2011) 56
5.6 Genetic Testing, Republic of Korea, Company Share (2010-2011) 57
6 Haematology In Republic of Korea 59
6.1 Haematology Market, Market Segmentation 59
6.2 Haematology Market, Republic of Korea, Revenue Mix ($m), 2011 60
6.3 Haematology Market, Republic of Korea, Segment Contribution (%), 2011 61
6.4 Haematology Overall Revenue, (2004-2018) 62
6.4.1 Haematology Reagents, Revenue (2004-2018) 66
6.4.2 Immunohaematology, Revenue (2004-2018) 70
6.4.3 Haemostasis, Revenue (2004-2018) 74
6.4.4 Haematology Rapid Tests, Revenue (2004-2018) 78
6.4.5 Haematology Cell Counters, Revenue (2004-2018) 82
6.5 Haematology Distribution Share (2010-2011) 86
6.6 Haematology, Republic of Korea, Company Share (2010-2011) 87
7 Histology And Cytology In Republic of Korea 89
7.1 Histology and Cytology Market, Market Segmentation 89
7.2 Histology And Cytology Market, Republic of Korea, Revenue Mix ($m), 2011 90
7.3 Histology And Cytology Market, Republic of Korea, Segment Contribution (%), 2011 91
7.4 Histology And Cytology Overall Revenue, (2004-2018) 92
7.5 Histology And Cytology Distribution Share (2010-2011) 96
7.6 Histology And Cytology, Republic of Korea, Company Share (2010-2011) 97
8 Immuno Chemistry In Republic of Korea 99
8.1 Immuno Chemistry Market, Republic of Korea, Revenue Mix ($m), 2011 99
8.2 Immuno Chemistry Market, Republic of Korea, Segment Contribution (%), 2011 100
8.3 Immuno Chemistry Overall Revenue, (2004-2018) 102
8.3.1 Disease Specific Immunochemistry, Revenue (2004-2018) 106
8.3.2 Drugs of Abuse / Toxicology, Revenue (2004-2018) 110
8.3.3 Endocrinology Tests, Revenue (2004-2018) 114
8.3.4 Immunochemistry Rapid Tests, Revenue (2004-2018) 118
8.3.5 Therapeutic Drug Monitoring, Revenue (2004-2018) 122
8.3.6 Immunochemistry Analyzers, Revenue (2004-2018) 126
8.4 Immuno Chemistry Distribution Share (2010-2011) 130
8.5 Immuno Chemistry, Republic of Korea, Company Share (2010-2011) 131
9 Infectious Immunology In Republic of Korea 133

4. 9.1 Infectious Immunology, Market Segmentation 133
9.2 Infectious Immunology Market, Republic of Korea, Revenue Mix ($m), 2011 134
9.3 Infectious Immunology Market, Republic of Korea, Segment Contribution (%), 2011 135
9.4 Infectious Immunology Overall Revenue, (2004-2018) 136
9.4.1 Infectious Immunology Rapid Tests, Revenue (2004-2018) 140
9.5 Infectious Immunology Distribution Share (2010-2011) 144
9.6 Infectious Immunology, Republic of Korea, Company Share (2010-2011) 145
10 Microbiology Culture In Republic of Korea 147
10.1 Microbiology Culture, Market Segmentation 147
10.2 Microbiology Culture Market, Republic of Korea, Revenue Mix ($m), 2011 148
10.3 Microbiology Culture Market, Republic of Korea, Segment Contribution (%), 2011 149
10.4 Microbiology Culture Overall Revenue, (2004-2018) 150
10.4.1 Microbiology Analyzers, Revenue (2004-2018) 154
10.5 Microbiology Culture Distribution Share (2010-2011) 158
10.6 Microbiology Culture, Republic of Korea, Company Share (2010-2011) 159
11 Overview of Key Companies in Republic of Korea In Vitro Diagnostics Market 161
11.1 F. Hoffmann-La Roche Ltd. 161
11.1.1 Company Overview 161
11.1.2 Share in the Republic of Korea In Vitro Diagnostics Market 161
11.2 Abbott Laboratories 162
11.2.1 Company Overview 162
11.2.2 Share in the Republic of Korea In Vitro Diagnostics Market 162
11.3 Siemens Healthcare 163
11.3.1 Company Overview 163
11.3.2 Share in the Republic of Korea In Vitro Diagnostics Market 163
11.4 Beckman Coulter, Inc. 164
11.4.1 Company Overview 164
11.4.2 Share in the Republic of Korea In Vitro Diagnostics Market 164
11.5 Sysmex Corporation 165
11.5.1 Company Overview 165
11.5.2 Share in the Republic of Korea In Vitro Diagnostics Market 165
11.6 Alere Inc. 166
11.6.1 Company Overview 166
11.6.2 Share in the Republic of Korea In Vitro Diagnostics Market 166
11.7 bioMerieux S.A. 167
11.7.1 Company Overview 167
11.8 Ortho-Clinical Diagnostics Inc. 167
11.8.1 Company Overview 167
11.9 Bio-Rad Laboratories, Inc. 168
11.9.1 Company Overview 168
11.10 Hitachi Medical Corporation 168
11.10.1 Company Overview 168

5. 11.11 Becton, Dickinson and Company 169
11.11.1 Company Overview 169
11.12 Toshiba Medical Systems Corporation 169
11.12.1 Company Overview 169
11.13 DiaSorin S.p.A 170
11.13.1 Company Overview 170
11.14 Qiagen N.V. 170
11.14.1 Company Overview 170
11.15 PerkinElmer, Inc. 171
11.15.1 Company Overview 171
11.16 Danaher Corporation 171
11.16.1 Company Overview 171
11.17 Mindray Medical International Limited 172
11.17.1 Company Overview 172
11.18 Thermo Fisher Scientific Inc. 172
11.18.1 Company Overview 172
11.19 Gen-Probe Incorporated 173
11.19.1 Company Overview 173
11.20 Nihon Kohden Corporation 173
11.20.1 Company Overview 173
11.21 Horiba, Ltd. 174
11.21.1 Company Overview 174
11.22 Life Technologies Corporation 174
11.22.1 Company Overview 174
11.23 Phadia AB 175
11.23.1 Company Overview 175
12 In Vitro Diagnostics Market Pipeline Products 176
12.1 Clinical Chemisty Market Pipeline Products 176
12.2 Immuno Chemistry Market Pipeline Products 179
12.3 Haematology Market Pipeline Products 190
12.4 Infectious Immunology Market Pipeline Products 192
12.5 Microbiology Culture Market Pipeline Products 199
12.6 Histology And Cytology Market Pipeline Products 200
12.7 Genetic Testing Market Pipeline Products 201
13 Financial Deals Landscape 206
13.1 Acquisition 206
13.1.1 Shanghai Fosun Pharma Acquires 17.65% Stake In SD Biosensor, In Vitro Diagnostics
Company 206
13.2 Partnerships 207
13.2.1 bioMerieux Enters Into Licensing Agreement With Quanterix For Simoa Technology 207
13.2.2 Affinity Biosensors Enters Into Distribution Agreement With Malvern Instruments For
Archimedes Particle Metrology System 209

6. 13.2.3 Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ 210
13.2.4 BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology
Assays 211
13.2.5 CellaVision Enters Into Distribution Agreement With Siemens Healthcare For Digital
Microscopy Hematology Solutions 212
13.2.6 Med BioGene Amends Licensing Agreement With Precision Therapeutics For LungExpress
Dx Test 214
13.2.7 Ovizio Imaging Systems Enters Into Distribution Agreement With Applikon Biotechnology
216
13.2.8 CML HealthCare Enters Into Agreement With MaRS Innovation 217
13.2.9 Akrivis Technologies Enters Into Co-Development Agreement With United States Biological
218
13.2.10 Castle Biosciences Enters Into Licensing Agreement With Brigham and Women''s Hospital
For Mesothelioma Test 219
13.2.11 Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For Protein
Array Products 220
13.2.12 GeneCentric Diagnostics Enters Into Licensing Agreement With University of North
Carolina 221
13.2.13 Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium TB
Test 222
13.2.14 Agilent Enters Into Co-Development Agreement With Gachon University For Biomarkers
223
13.2.15 SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich For
PhenoFluor 224
13.2.16 Sysmex Asia Pacific Enters Into Distribution Agreement With DiaSys Diagnostic Systems
225
13.2.17 Immuno-Biological Labs Enters Into Licensing Agreement With IBL International 226
13.2.18 MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test 227
13.2.19 NicOx Enters Into Licensing Agreement With Rapid Pathogen Screening For AdenoPlus
228
13.2.20 Immunexpress Enters Into Licensing Agreement With Debiopharm And Biocartis 230
13.2.21 Omega Diagnostics Enters Into Licensing Agreement With Burnet Institute For CD4 POC
Test 232
13.2.22 One Lambda Enters Into Co-Marketing Agreement With CellTrend 233
13.2.23 Clarient Diagnostic Services Enters Into Licensing Agreement With Insight Genetics For
ALK Cancer Biomarker 234
13.2.24 Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems 235
13.2.25 Seegene Enters Into Co-Development Agreement With DuPont Nutrition & Health To
Develop Multiplexed Assays For Food Safety Testing 236
13.2.26 Ventana Medical Enters Into Licensing Agreement With Gen-Probe For IP Of ERG Marker
237
13.2.27 Affymetrix Enters Into Distribution Agreement With ScreenCell For Circulating Tumor Cell

7. Technology 238
13.2.28 Hycor Biomedical Enters Into Distribution Agreement With Roche For KOVA 239
13.2.29 Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For LongRange
PCR Kit 240
13.2.30 Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo 241
13.2.31 Pressure BioSciences Enters Into Licensing Agreement With Target Discovery For
Pressure Cycling Technology 242
13.2.32 LipoScience Enters Into Licensing Agreement With Cleveland Clinic 244
13.2.33 GE Healthcare Enters Into Co-Development Agreement With NXT2B For Compact
Cyclotron And PET Tracer System 245
13.2.34 NexDx Enters Into Licensing Agreement With University of California For Epigenetic
Biomarkers 246
13.2.35 Bio-Rad Labs Extends Distribution Agreement With Luminex For MAGPIX 247
14 Appendix 248
14.1 Definitions of Markets Covered in the Report 249
14.1.1 In Vitro Diagnostics 249
14.2 Research Methodology 260
14.3 Secondary Research 260
14.4 Primary Research 261
14.5 Models 261
14.6 Forecasts 262
14.7 Expert Panels 262
14.8 GlobalData Consulting 262
14.9 Currency Conversion 263
14.10 Contact Us 263
14.11 Disclaimer 263
1.1 List of Tables
Table 1: In Vitro Diagnostics, Republic of Korea, Overall Revenue ($m), USD Constant, 2004-
2018 20
Table 2: In Vitro Diagnostics Market, Republic of Korea, Category Contribution (%), 2011 22
Table 3: In Vitro Diagnostics Market, Republic of Korea, Cross-Category Analysis, 2004-2018 24
Table 4: In Vitro Diagnostics, Republic of Korea, Overall Revenue ($m), USD Constant, Historic,
2004-2011 26
Table 5: In Vitro Diagnostics, Republic of Korea, Overall Revenue ($m), USD Constant, Forecast,
2011-2018 28
Table 6: In Vitro Diagnostics, Republic of Korea, Company Share by Revenue ($m), USD
Constant, 2010-2011 30
Table 7: Clinical Chemistry Market, Republic of Korea, Segment Contribution (%), 2011 33
Table 8: Clinical Chemistry, Republic of Korea, Revenue ($m) USD Constant, by Segment,
Historic, 2004-2011 35
Table 9: Clinical Chemistry, Republic of Korea, Revenue ($m) USD Constant, by Segment,

8. Forecast, 2011-2018 37
Table 10: Clinical Chemisty Analyzers, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 39
Table 11: Clinical Chemisty Analyzers, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 41
Table 12: Urine Analysis, Republic of Korea, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 43
Table 13: Urine Analysis, Republic of Korea, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 45
Table 14: Clinical Chemistry, Republic of Korea, Distribution Share by Revenue ($m), USD
Constant, 2010-2011 46
Table 15: Clinical Chemistry, Republic of Korea, Company Share by Revenue ($m), USD
Constant, 2010-2011 48
Table 16: Genetic Testing Market, Republic of Korea, Segment Contribution (%), 2011 51
Table 17: Genetic Testing, Republic of Korea, Revenue ($m) USD Constant, by Segment, Historic,
2004-2011 53
Table 18: Genetic Testing, Republic of Korea, Revenue ($m) USD Constant, by Segment,
Forecast, 2011-2018 55
Table 19: Genetic Testing, Republic of Korea, Distribution Share by Revenue ($m), USD
Constant, 2010-2011 56
Table 20: Genetic Testing, Republic of Korea, Company Share by Revenue ($m), USD Constant,
2010-2011 58
Table 21: Haematology Market, Republic of Korea, Segment Contribution (%), 2011 61
Table 22: Haematology, Republic of Korea, Revenue ($m) USD Constant, by Segment, Historic,
2004-2011 63
Table 23: Haematology, Republic of Korea, Revenue ($m) USD Constant, by Segment, Forecast,
2011-2018 65
Table 24: Haematology Reagents, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 67
Table 25: Haematology Reagents, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 69
Table 26: Immunohaematology, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 71
Table 27: Immunohaematology, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 73
Table 28: Haemostasis, Republic of Korea, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 75
Table 29: Haemostasis, Republic of Korea, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 77
Table 30: Haematology Rapid Tests, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 79
Table 31: Haematology Rapid Tests, Republic of Korea, Revenue ($m) USD Constant, by Sub-

9. Segment, Forecast, 2011-2018 81
Table 32: Haematology Cell Counters, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 83
Table 33: Haematology Cell Counters, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 85
Table 34: Haematology, Republic of Korea, Distribution Share by Revenue ($m), USD Constant,
2010-2011 86
Table 35: Haematology, Republic of Korea, Company Share by Revenue ($m), USD Constant,
2010-2011 88
Table 36: Histology And Cytology Market, Republic of Korea, Segment Contribution (%), 2011 91
Table 37: Histology And Cytology, Republic of Korea, Revenue ($m) USD Constant, by Segment,
Historic, 2004-2011 93
Table 38: Histology And Cytology, Republic of Korea, Revenue ($m) USD Constant, by Segment,
Forecast, 2011-2018 95
Table 39: Histology And Cytology, Republic of Korea, Distribution Share by Revenue ($m), USD
Constant, 2010-2011 96
Table 40: Histology And Cytology, Republic of Korea, Company Share by Revenue ($m), USD
Constant, 2010-2011 98
Table 41: Immuno Chemistry Market, Republic of Korea, Segment Contribution (%), 2011 101
Table 42: Immuno Chemistry, Republic of Korea, Revenue ($m) USD Constant, by Segment,
Historic, 2004-2011 103
Table 43: Immuno Chemistry, Republic of Korea, Revenue ($m) USD Constant, by Segment,
Forecast, 2011-2018 105
Table 44: Disease Specific Immunochemistry, Republic of Korea, Revenue ($m) USD Constant,
by Sub-Segment, Historic, 2004-2011 107
Table 45: Disease Specific Immunochemistry, Republic of Korea, Revenue ($m) USD Constant,
by Sub-Segment, Forecast, 2011-2018 109
Table 46: Drugs of Abuse / Toxicology, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 111
Table 47: Drugs of Abuse / Toxicology, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 113
Table 48: Endocrinology Tests, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 115
Table 49: Endocrinology Tests, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 117
Table 50: Immunochemistry Rapid Tests, Republic of Korea, Revenue ($m) USD Constant, by
Sub-Segment, Historic, 2004-2011 119
Table 51: Immunochemistry Rapid Tests, Republic of Korea, Revenue ($m) USD Constant, by
Sub-Segment, Forecast, 2011-2018 121
Table 52: Therapeutic Drug Monitoring, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 123
Table 53: Therapeutic Drug Monitoring, Republic of Korea, Revenue ($m) USD Constant, by Sub-

10. Segment, Forecast, 2011-2018 125
Table 54: Immunochemistry Analyzers, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 127
Table 55: Immunochemistry Analyzers, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 129
Table 56: Immuno Chemistry, Republic of Korea, Distribution Share by Revenue ($m), USD
Constant, 2010-2011 130
Table 57: Immuno Chemistry, Republic of Korea, Company Share by Revenue ($m), USD
Constant, 2010-2011 132
Table 58: Infectious Immunology Market, Republic of Korea, Segment Contribution (%), 2011 135
Table 59: Infectious Immunology, Republic of Korea, Revenue ($m) USD Constant, by Segment,
Historic, 2004-2011 137
Table 60: Infectious Immunology, Republic of Korea, Revenue ($m) USD Constant, by Segment,
Forecast, 2011-2018 139
Table 61: Infectious Immunology Rapid Tests, Republic of Korea, Revenue ($m) USD Constant,
by Sub-Segment, Historic, 2004-2011 141
Table 62: Infectious Immunology Rapid Tests, Republic of Korea, Revenue ($m) USD Constant,
by Sub-Segment, Forecast, 2011-2018 143
Table 63: Infectious Immunology, Republic of Korea, Distribution Share by Revenue ($m), USD
Constant, 2010-2011 144
Table 64: Infectious Immunology, Republic of Korea, Company Share by Revenue ($m), USD
Constant, 2010-2011 146
Table 65: Microbiology Culture Market, Republic of Korea, Segment Contribution (%), 2011 149
Table 66: Microbiology Culture, Republic of Korea, Revenue ($m) USD Constant, by Segment,
Historic, 2004-2011 151
Table 67: Microbiology Culture, Republic of Korea, Revenue ($m) USD Constant, by Segment,
Forecast, 2011-2018 153
Table 68: Microbiology Analyzers, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 155
Table 69: Microbiology Analyzers, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 157
Table 70: Microbiology Culture, Republic of Korea, Distribution Share by Revenue ($m), USD
Constant, 2010-2011 158
Table 71: Microbiology Culture, Republic of Korea, Company Share by Revenue ($m), USD
Constant, 2010-2011 160
Table 72: Clinical Chemisty Market Pipeline Products 176
Table 73: Immuno Chemistry Market Pipeline Products 179
Table 74: Haematology Market Pipeline Products 190
Table 75: Infectious Immunology Market Pipeline Products 192
Table 76: Microbiology Culture Market Pipeline Products 199
Table 77: Histology And Cytology Market Pipeline Products 200
Table 78: Genetic Testing Market Pipeline Products 201

11. Table 79: Shanghai Fosun Pharma Acquires 17.65% Stake In SD Biosensor, In Vitro Diagnostics
Company 206
Table 80: bioMerieux Enters Into Licensing Agreement With Quanterix For Simoa Technology 207
Table 81: Affinity Biosensors Enters Into Distribution Agreement With Malvern Instruments For
Archimedes Particle Metrology System 209
Table 82: Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ 210
Table 83: BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology
Assays 211
Table 84: CellaVision Enters Into Distribution Agreement With Siemens Healthcare For Digital
Microscopy Hematology Solutions 212
Table 85: Med BioGene Amends Licensing Agreement With Precision Therapeutics For
LungExpress Dx Test 214
Table 86: Ovizio Imaging Systems Enters Into Distribution Agreement With Applikon
Biotechnology 216
Table 87: CML HealthCare Enters Into Agreement With MaRS Innovation 217
Table 88: Akrivis Technologies Enters Into Co-Development Agreement With United States
Biological 218
Table 89: Castle Biosciences Enters Into Licensing Agreement With Brigham and Women''s
Hospital For Mesothelioma Test 219
Table 90: Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For Protein
Array Products 220
Table 91: GeneCentric Diagnostics Enters Into Licensing Agreement With University of North
Carolina 221
Table 92: Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium
TB Test 222
Table 93: Agilent Enters Into Co-Development Agreement With Gachon University For Biomarkers
223
Table 94: SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich For
PhenoFluor 224
Table 95: Sysmex Asia Pacific Enters Into Distribution Agreement With DiaSys Diagnostic
Systems 225
Table 96: Immuno-Biological Labs Enters Into Licensing Agreement With IBL International 226
Table 97: MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test
227
Table 98: NicOx Enters Into Licensing Agreement With Rapid Pathogen Screening For AdenoPlus
228
Table 99: Immunexpress Enters Into Licensing Agreement With Debiopharm And Biocartis 230
Table 100: Omega Diagnostics Enters Into Licensing Agreement With Burnet Institute For CD4
POC Test 232
Table 101: One Lambda Enters Into Co-Marketing Agreement With CellTrend 233
Table 102: Clarient Diagnostic Services Enters Into Licensing Agreement With Insight Genetics
For ALK Cancer Biomarker 234

12. Table 103: Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems 235
Table 104: Seegene Enters Into Co-Development Agreement With DuPont Nutrition & Health To
Develop Multiplexed Assays For Food Safety Testing 236
Table 105: Ventana Medical Enters Into Licensing Agreement With Gen-Probe For IP Of ERG
Marker 237
Table 106: Affymetrix Enters Into Distribution Agreement With ScreenCell For Circulating Tumor
Cell Technology 238
Table 107: Hycor Biomedical Enters Into Distribution Agreement With Roche For KOVA 239
Table 108: Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For
LongRange PCR Kit 240
Table 109: Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo 241
Table 110: Pressure BioSciences Enters Into Licensing Agreement With Target Discovery For
Pressure Cycling Technology 242
Table 111: LipoScience Enters Into Licensing Agreement With Cleveland Clinic 244
Table 112: GE Healthcare Enters Into Co-Development Agreement With NXT2B For Compact
Cyclotron And PET Tracer System 245
Table 113: NexDx Enters Into Licensing Agreement With University of California For Epigenetic
Biomarkers 246
Table 114: Bio-Rad Labs Extends Distribution Agreement With Luminex For MAGPIX 247
1.2 List of Figures
Figure 1: In Vitro Diagnostics, Market Segmentation 18
Figure 2: In Vitro Diagnostics, Republic of Korea, Overall Revenue ($m), USD Constant, 2004-
2018 19
Figure 3: In Vitro Diagnostics Market, Republic of Korea, Revenue Mix ($m), 2011 21
Figure 4: In Vitro Diagnostics Market, Republic of Korea, Category Contribution (%), 2011 22
Figure 5: In Vitro Diagnostics Market, Republic of Korea, Cross-Category Analysis, 2004-2018 23
Figure 6: In Vitro Diagnostics, Republic of Korea, Overall Revenue ($m), USD Constant, Historic,
2004-2011 25
Figure 7: In Vitro Diagnostics, Republic of Korea, Overall Revenue ($m), USD Constant, Forecast,
2011-2018 27
Figure 8: In Vitro Diagnostics, Republic of Korea, Company Share (%), 2011 29
Figure 9: Clinical Chemistry, Market Segmentation 31
Figure 10: Clinical Chemistry Market, Republic of Korea, Revenue Mix ($m), 2011 32
Figure 11: Clinical Chemistry Market, Republic of Korea, Segment Contribution (%), 2011 33
Figure 12: Clinical Chemistry, Republic of Korea, Revenue ($m) USD Constant, by Segment,
Historic, 2004-2011 34
Figure 13: Clinical Chemistry, Republic of Korea, Revenue ($m) USD Constant, by Segment,
Forecast, 2011-2018 36
Figure 14: Clinical Chemisty Analyzers, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 38
Figure 15: Clinical Chemisty Analyzers, Republic of Korea, Revenue ($m) USD Constant, by Sub-

13. Segment, Forecast, 2011-2018 40
Figure 16: Urine Analysis, Republic of Korea, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 42
Figure 17: Urine Analysis, Republic of Korea, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 44
Figure 18: Clinical Chemistry, Republic of Korea, Company Share (%), 2011 47
Figure 19: Genetic Testing, Market Segmentation 49
Figure 20: Genetic Testing Market, Republic of Korea, Revenue Mix ($m), 2011 50
Figure 21: Genetic Testing Market, Republic of Korea, Segment Contribution (%), 2011 51
Figure 22: Genetic Testing, Republic of Korea, Revenue ($m) USD Constant, by Segment,
Historic, 2004-2011 52
Figure 23: Genetic Testing, Republic of Korea, Revenue ($m) USD Constant, by Segment,
Forecast, 2011-2018 54
Figure 24: Genetic Testing, Republic of Korea, Company Share (%), 2011 57
Figure 25: Haematology Market, Market Segmentation 59
Figure 26: Haematology Market, Republic of Korea, Revenue Mix ($m), 2011 60
Figure 27: Haematology Market, Republic of Korea, Segment Contribution (%), 2011 61
Figure 28: Haematology, Republic of Korea, Revenue ($m) USD Constant, by Segment, Historic,
2004-2011 62
Figure 29: Haematology, Republic of Korea, Revenue ($m) USD Constant, by Segment, Forecast,
2011-2018 64
Figure 30: Haematology Reagents, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 66
Figure 31: Haematology Reagents, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 68
Figure 32: Immunohaematology, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 70
Figure 33: Immunohaematology, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 72
Figure 34: Haemostasis, Republic of Korea, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 74
Figure 35: Haemostasis, Republic of Korea, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 76
Figure 36: Haematology Rapid Tests, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 78
Figure 37: Haematology Rapid Tests, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 80
Figure 38: Haematology Cell Counters, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 82
Figure 39: Haematology Cell Counters, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 84
Figure 40: Haematology, Republic of Korea, Company Share (%), 2011 87

14. Figure 41: Histology and Cytology Market, Market Segmentation 89
Figure 42: Histology And Cytology Market, Republic of Korea, Revenue Mix ($m), 2011 90
Figure 43: Histology And Cytology Market, Republic of Korea, Segment Contribution (%), 2011 91
Figure 44: Histology And Cytology, Republic of Korea, Revenue ($m) USD Constant, by Segment,
Historic, 2004-2011 92
Figure 45: Histology And Cytology, Republic of Korea, Revenue ($m) USD Constant, by Segment,
Forecast, 2011-2018 94
Figure 46: Histology And Cytology, Republic of Korea, Company Share (%), 2011 97
Figure 47: Immuno Chemistry Market, Republic of Korea, Revenue Mix ($m), 2011 99
Figure 48: Immuno Chemistry Market, Republic of Korea, Segment Contribution (%), 2011 100
Figure 49: Immuno Chemistry, Republic of Korea, Revenue ($m) USD Constant, by Segment,
Historic, 2004-2011 102
Figure 50: Immuno Chemistry, Republic of Korea, Revenue ($m) USD Constant, by Segment,
Forecast, 2011-2018 104
Figure 51: Disease Specific Immunochemistry, Republic of Korea, Revenue ($m) USD Constant,
by Sub-Segment, Historic, 2004-2011 106
Figure 52: Disease Specific Immunochemistry, Republic of Korea, Revenue ($m) USD Constant,
by Sub-Segment, Forecast, 2011-2018 108
Figure 53: Drugs of Abuse / Toxicology, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 110
Figure 54: Drugs of Abuse / Toxicology, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 112
Figure 55: Endocrinology Tests, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 114
Figure 56: Endocrinology Tests, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 116
Figure 57: Immunochemistry Rapid Tests, Republic of Korea, Revenue ($m) USD Constant, by
Sub-Segment, Historic, 2004-2011 118
Figure 58: Immunochemistry Rapid Tests, Republic of Korea, Revenue ($m) USD Constant, by
Sub-Segment, Forecast, 2011-2018 120
Figure 59: Therapeutic Drug Monitoring, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 122
Figure 60: Therapeutic Drug Monitoring, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 124
Figure 61: Immunochemistry Analyzers, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 126
Figure 62: Immunochemistry Analyzers, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 128
Figure 63: Immuno Chemistry, Republic of Korea, Company Share (%), 2011 131
Figure 64: Infectious Immunology, Market Segmentation 133
Figure 65: Infectious Immunology Market, Republic of Korea, Revenue Mix ($m), 2011 134
Figure 66: Infectious Immunology Market, Republic of Korea, Segment Contribution (%), 2011 135

15. Figure 67: Infectious Immunology, Republic of Korea, Revenue ($m) USD Constant, by Segment,
Historic, 2004-2011 136
Figure 68: Infectious Immunology, Republic of Korea, Revenue ($m) USD Constant, by Segment,
Forecast, 2011-2018 138
Figure 69: Infectious Immunology Rapid Tests, Republic of Korea, Revenue ($m) USD Constant,
by Sub-Segment, Historic, 2004-2011 140
Figure 70: Infectious Immunology Rapid Tests, Republic of Korea, Revenue ($m) USD Constant,
by Sub-Segment, Forecast, 2011-2018 142
Figure 71: Infectious Immunology, Republic of Korea, Company Share (%), 2011 145
Figure 72: Microbiology Culture, Market Segmentation 147
Figure 73: Microbiology Culture Market, Republic of Korea, Revenue Mix ($m), 2011 148
Figure 74: Microbiology Culture Market, Republic of Korea, Segment Contribution (%), 2011 149
Figure 75: Microbiology Culture, Republic of Korea, Revenue ($m) USD Constant, by Segment,
Historic, 2004-2011 150
Figure 76: Microbiology Culture, Republic of Korea, Revenue ($m) USD Constant, by Segment,
Forecast, 2011-2018 152
Figure 77: Microbiology Analyzers, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 154
Figure 78: Microbiology Analyzers, Republic of Korea, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 156
Figure 79: Microbiology Culture, Republic of Korea, Company Share (%), 2011 159
Figure 80: F. Hoffmann-La Roche Ltd., Company Share (%),Republic of Korea In Vitro Diagnostics
Market, 2011 161
Figure 81: Abbott Laboratories, Company Share (%),Republic of Kor
Contact: sales@reportsandreports.com for more information.